









































Pa
ge

 
1



Pa
ge

 
78

American Journal of  Medical 
Science and Innovation (AJMSI) 

Indication of  laboratory parameters for kidney diseases at King Fahad Medical 
City, Riyadh, Saudi Arabia

Yousef  Sultan Alobaisi1*, Firoz Anwar2, Khaled Dabour3, Khalid Almatham4, Sultan Alshahrani1, Khalid A. Alzahrani5

Yasir Awad Ahmed1, Maher Mohammed Alobaysi6

Volume 4 Issue 2, Year 2025
ISSN: 2836-8509 (Online)

DOI: https://doi.org/10.54536/ajmsi.v4i2.5340
https://journals.e-palli.com/home/index.php/ajmsi

Article Information ABSTRACT

Received: June 02, 2025
Accepted: July 04, 2025
Published: October 22, 2025

End-stage renal disease (ESRD), chronic kidney disease (CKD), and acute kidney failure 
(AKF) are serious global health issues that contribute to high sickness and death rates. This 
King Fahad Medical City study investigated the importance of  reliable biomarker monitoring 
and early treatment to enhance patient outcomes. 220 people had their serum levels of  
albumin, C-reactive protein (CRP), urea, creatinine, salt and phosphate assessed. Creatinine 
(χ² = 60.73, p < 0.001), urea (χ² = 48.66, p < 0.001), phosphate (χ² = 19.20, p = 0.004), 
sodium (χ² = 14.10, p = 0.029) and body weight (χ² = 13.24, p = 0.039) showed significant 
differences across diagnostic groups, according to the Kruskal-Wallis test. Significant activity 
was indicated by the highest CRP values (103.9 mg/L; 95% CI: 83.9–123.9 mg/L) in AKF 
patients, whereas the highest average creatinine levels (428.6 µmol/L; 95% CI: 330.0–527.2 
µmol/L) were seen in ESRD patients. The above results show that every disease has an 
unique biomarker signature. Also a gender study revealed that, on average, male patients 
weighed 7.29 kg heavier than female patients (t = 2.739, p = 0.007). The study shows 
that kidney-related illnesses may be effectively treated with biomarker-based diagnostics.
Important biomarkers for CKD, ESRD and AKF detection include creatinine, urea, CRP 
and sodium. This highlights how helpful these indicators are for supporting timely diagnosis, 
improving clinical intervention techniques and directing customized treatment plans.

Keywords
Acute Kidney Failure (AKF), 
Chronic Kidney Disease (CKD), 
End Stage Renal Disease 
(ESRD), Laboratory Biomarkers

1 King Fahad Medical City, Pathology and Clinical Laboratory Medicine Administration, Riyadh, 11525, Saudi Arabia
2 King Abdulaziz University, Department of  Biochemistry, Faculty of  Science, Jeddah, Saudi Arabia 
3 Tanta University, Department of  Entomology, Faculty of  Science, Tanta, 31527, Egypt
4 King Fahad Medical City, Department of  Nephrology, Riyadh, 11525, Saudi Arabia
5 King Fahad Medical City, Department of  Electronic Medical Records (EMR), Riyadh, Saudi Arabia
6 King Fahad Medical City, Simulation Development Department, Academic and Training Affairs, Riyadh, 11525, Saudi Arabia
* Corresponding author’s e-mail: yalobaisi@kfmc.med.sa

INTRODUCTION
Chronic kidney disease (CKD) and end-stage kidney 
disease (ESRD) continue to be major global health 
challenge, significantly contributing to the overall 
burden of  morbidity, mortality, and the cost of  health 
care with CKD affecting approximately 13.4% of  the 
worldwide population which together is estimated to be 
over 700 million people living with some form of  kidney 
disease (Kovesdy, 2022). ESRD Prevalence varies but is 
increasing, with approximately 2 million people currently 
on dialysis and expected to increase in the coming years 
(Filipska et al., 2021). The high and growing rates of  
diabetes mellitus, hypertension and the aging population 
are the main causes of  the worrying rise in kidney disease 
frequency, according to recent epidemiological data 
(Major et al., 2018; Webster et al., 2017). Chronic kidney 
disease (CKD) is the third most commonly seen and 
biggest disorder globally, behind heart disease and cancer, 
according to clinical data analysis (Jiang et al., 2023). 
According to Al-Sayyari and Shaheen (2011), the high 
incidence of  risk factors such as obesity and metabolic 
syndrome worsens the increasing rate of  renal disease in 
Saudi Arabia. 
Reducing the burden of  illness still demands thorough 
analysis of  renal functions, timely identification of  kidney 

disease, and progress in the disease. Indicators such as 
serum creatinine and urea are crucial to conventional 
methods. A increase in serum creatinine, a sign of  a low 
glomerular filtration rate (GFR), remains one of  the 
most significant markers of  renal impairment (Wang et 
al., 2019). However, these standard markers are either 
too general or too specific to identify the kind of  kidney 
damage or in the early stages of  the illness (Mizdrak et al., 
2022). Therefore, the need for stronger biomarker panels 
is growing in order to provide rapid, accurate, sensitive 
and comprehensive diagnostic medical information.
Between 2022 and 2024, new biomarkers and the 
improvement of  current ones have become more 
popular in an effort to improve diagnostic and prognostic 
capacities. According to Gremese et al. (2023), there is 
potential for improving the detection of  renal illness 
by using indicators of  inflammation, problems with 
electrolytes and nutritional status. Due to their high 
relationship with the course of  the illness and risk for 
heart disease, biomarkers that show inflammation and 
mortality in patients with CKD and ESRD, including 
C-reactive protein (CRP), are now among the most 
significant (Li et al., 2023; Stenvinkel et al., 2021).
Electrolyte issues involving sodium, phosphate, calcium 
and albumin are among the primary causes of  CKD 



Pa
ge

 
79

https://journals.e-palli.com/home/index.php/ajmsi

Am. J. Med. Sci. Innov. 4(2) 78-88, 2025

impacts, including mineral and bone diseases and 
cardiovascular diseases. As chronic kidney disease (CKD) 
is becoming more common and has a significant impact 
on healthcare systems, better methods of  diagnosis 
and treatment must be developed. Early identification, 
treatment of  underlying causes and secondary prevention 
measures can stop or even prevent the development 
of  the condition (Bektay et al., 2024). More complex 
methods are encouraged by recent KDIGO guidelines, 
which stress the active continual tracking of  these 
biomarkers and concentrate on therapy based on trends 
rather than single values (Valson et al., 2020). Despite the 
guidelines, there is a lack of  more thorough research that 
look at how kidney disease handles change when markers 
alter in a clinical environment and commitment to these 
recommendations differs.
This study addresses explicitly these existing limitations 
by examining and profiling several critical biomarkers, 
including creatinine, urea, C-reactive protein (CRP), 
albumin, sodium, calcium, and phosphate in patients 
with chronic kidney disease stages 3 to 5, end stage renal 
disease, acute kidney failure, acute nephritic syndrome, 
chronic renal failure-associated anemia, and septic shock.  
The primary goal of  this study is to identify distinct 
patterns and variations in indicators associated with 
specific renal disorders, thereby aiding in the further 
refinement of  diagnostic precision, tailoring management 
levels, and optimizing clinical outcomes for patients.
The primary hypothesis is that there is a notable 
variation in biomarkers among different renal disorders, 
corresponding to distinct underlying pathophysiological 
processes. In addition, we also hypothesize that 
systematically profiling biomarkers will add more value in 
predicting superior diagnostic and prognostic information 
compared to traditional isolated biomarker assessments.
The study’s findings are meant to help individuals by 
providing explanation on some choices regarding the 
implementation of  early treatment interventions, the 
customization of  therapies, and the use of  pertinent 
biomarker trends and variations across various kidney 
disease types to track the progression of  the disease. 
In the end, these discoveries may lead to better clinical 
procedures and established care models for kidney disease 
management, which would greatly improve nephrology 
patient care and results.

LITERATURE REVIEW
Chronic kidney disease (CKD) poses an increasingly 
prevalent global health concern, creating problems for 
healthcare systems due to the chronic health subjects, the 
costly nature of  treatment, and progressive deterioration 
of  renal functions (Kuo & Chapman, 2020; Major et al., 
2018). Kidneys are of  great physiological homeostasis 
maintenances through removing metabolic waste like 
urea, creatinine, uric acid, and regulates fluid volune and 
sodium level, serum osmolality and secretes hormones 
like erythropoietin, vitamin D, and renin (Okoro & 
Farate, 2019; Webster et al., 2017).

The increase prevalence of  chronic kidney disease 
(CKD) is closely associated with the elderly population 
alongside the increase in chronic illnesses, such as diabetes 
and hypertension which are May risk factors for CKD 
progression (Major et al., 2018). Recently some studies have 
highlighted lifestyle factors such as obesity and smoking 
towards the development and progression of  CKD (Li et al., 
2023), Such factors lead to a higher population of  patients 
progressing towards CKD stage 5 which necessitates renal 
replacement therapies, such as dialysis or transplantation 
(Schrauben et al., 2022). The economic burden of  
population suffering from CKD is considerable because 
of  the expenditures associated with its management and 
complications (Zhang & Parikh, 2019). 
Moreover, latest insights in nephrology emphasize the 
importance of  proactive chronic kidney disease (CKD) 
management, including early diagnosis and stratified 
interventions. This includes the new digital health 
assets and technologies that support enhanced patient 
engagement and interface as well as newer biomarkers 
for prompt diagnosis (Chen et al., 2021; Wang et al., 
2019; Zhang & Parikh, 2019). The interconnections 
between diverse risk factors and various biomarkers are 
complex, and their understanding helps design efficient 
control methods for CKD and alleviating its global health 
challenges.
As CKD progresses, its complications widen systemically, 
foremost in importance is CKD-Mineral Bone Disorder 
(CKD-MBD). Along with bone and vascular problems 
CKD-MBD is caused by disruptions in the metabolism 
of  calcium, phosphate, parathyroid hormone (PTH) and 
vitamin D (Valson et al., 2020). The burden of  illness and 
death increases significantly by these chronic alterations. 
Hence, their continuous monitoring is important because 
of  the precision needed. 
Management of  CKD-MBD is directed towards managing 
each facet of  the enduring mineral bone relationship. 
Recent publications focus more on the need for 
cardiovascular complication and bone disease detection 
and intervention at earlier stages (Kuo & Chapman, 2020).  
In CKD patients, serum creatinine and urea are used to 
track electrolytes such calcium, phosphate, potassium 
and sodium as well as kidney function (Wang et al., 2019). 
Also, C-reactive protein (CRP), which is more prominent 
in chronic kidney disease (CKD) and is associated with 
increased cardiovascular risk, can be employed as a sign 
of  inflammation (Stenvinkel et al., 2021). The chances 
of  renal illnesses, cardiovascular problems and disease 
progression are all closely associated with high levels of  
CRP (Li et al., 2023; Tang et al., 2018).
Another recent emphasis has been placed on the value of  
albumin as more than a nutritional status measure but as 
a prognostic marker of  patients with renal disease. In case 
of  CKD, serum albumin levels are decreased on account 
of  malnutrition and inflammation, which are risk factors 
closely related to poor clinical outcomes, higher mortality 
rates, and poor life expectancy (Gremese et al., 2023).
Earlier studies have led to progress regarding biomarkers’ 



Pa
ge

 
80

https://journals.e-palli.com/home/index.php/ajmsi

Am. J. Med. Sci. Innov. 4(2) 78-88, 2025

usefulness in renal diseases. A study by Dublin Acute 
Biomarker Group Evaluation (DAMAGE) was done 
as proof  of  progressive potential of  different urinary 
biomarkers in critically ill patients at ICU as predictor 
of  acute kidney injury (AKI). Urinary markers such 
as NGAL, cystatin C, KIM-1 and albumin were able 
to predict progression of  AKI seven days after ICU 
admission, which is an important prognosticator as 
well as a marker associated with earlier development 
of  AKI (McMahon et al., 2019). Similarly, another 
researcher performed follow-up secondary analysis also 
found interleukin-18, NGAL, cystatin C and monocyte 
chemotactic protein 1 to be important predictors of  
progression to AKI with the consequences of  AKI. This 
underscores the possibility of  these biomarkers to be 
used in clinical risk stratification (Duff  et al., 2022).
Inflammatory markers such as CRP have been 
emphasized by different studies to be related to disease 
processes beyond inflammatory markers. For example, 
this second evidence adds to the fact that CRP is more 
than a passive marker and contributory to renal pathology 
since it confirmed its role in preserving insulin resistance, 
metabolic disorders and renal fibrosis (Tang et al., 2018).
While a lot work has been done for the progression of  
biomarker research to highlight their usefulness in the early 
detection of  kidney disease, there still remain substantial 
gaps in research especially for diverse populations of  
kidney diseases. Few prior attempts have been made to 
only on single biomarker and did not take into account 
a multifaceted approach. In addition to this, many of  
the existing literature lacks essential cross comparative 
studies on multiple renal diseases and therefore the 
specificity and clinical impact of  the diagnosis remains 
relatively lacking. Still, limitations in precision medicine 
due to deficiency in clarity, particularly on the landscape 
of  biomarker differences between truly acute kidney 
failure and chronic conditions such as ESRD or CKD, 
prevent development of  precision medicine, as necessary 
to personalized treatment design and adaptive clinical 
treatment approaches..
The main objective of  this study is to address 
these identified gaps by evaluating and comparing 
comprehensive biomarker profile comprising of  serum 
creatinine, urea, sodium, CRP, albumin, phosphate, and 
calcium in various renal conditions. This research has 
tried to improve diagnostic accuracy, increase prognostic 
power and identify strategies that might inform 
personalised therapeutic interventions leading to positive 
contribution in nephrology clinical practice guidelines.

MATERIALS AND METHODS
Study Design
The cross sectional observational study design was used 
in this research to see and evaluate biomarker profiles 
in patients with differing renal disorders. The study 
was performed in King Fahad Medical City (KFMC), 
Riyadh, Saudi Arabia that provides a heterogeneous 
patient population with advanced and up to date clinical 
laboratory facilities.

Study Participants
This study relied on biomarker data from 220 participants 
who were selected based on some pre-defined inclusion 
and exclusion criteria. Adult patients (18 years of  age and 
up) who visited King Fahad Medical City’s nephrology 
clinics between January and June of  2023 were chosen 
as participants. Patients with specific stages of  chronic 
kidney disease (CKD) such as stage 3–5 CKD, acute 
kidney failure, nephritic syndrome, end-stage renal disease 
(ESRD), chronic renal failure with anemia and septic 
shock are included in this category. A detailed clinical 
evaluation using stratified diagnostic scaffolds compliant 
with KDIGO 2017 guidelines was performed by 
renowned nephrologists for the purpose of  categorizing 
the patients enrolled in the study.

Inclusion and Exclusion Criteria
The study Inclusion criteria comprise patients aged 18 
years and above and suffering from different kidney 
diseases such as Chronic Kidney Disease (CKD), End 
Stage Renal Disease (ESRD), Acute Kidney Failure, Acute 
Nephritic Syndrome, and Anemia secondary to Chronic 
Renal Failure. This diagnosis was secured through a 
combination of  clinical assessment as well as laboratory 
data analysis. A patient’s glomerular filtration rate (GFR) 
was used to establish them as CKD stage 3-5 or confirm 
them as having ESRD if  they were dialysis dependent or 
had GFR less than 15 mL/min/1.73 m². Based on the 
acute rise in serum creatinine and the urinary output 
changes, acute kidney failure was identified. 
The study excluded patients who had either active 
infections, malignancies, severe cardiovascular diseases, 
hepatic disorders, or any other acute illness that could 
affect biomarker profiles. Pregnant women, together with 
patients receiving immunosuppressive treatment, were 
excluded from the study to prevent laboratory parameter 
interference.

Data Collection and Laboratory Analysis
With respect to the clinical care protocol for patients 
with CKD at King Fahad Medical City, routine laboratory 
assessments were performed to evaluate the level of  
specific biomarkers of  interest. Blood samples were 
drawn from study participants by qualified phlebotomists 
employing standard techniques to ensure accuracy and 
proper protocol to yield reliable results (Wright et al., 2019). 
Following biomarkers were taken into consideration.

Creatinine
As a leading indication of  kidney function, it is assessed 
using enzymatic assays. High concentrations of  creatinine 
mark a reduction in functional renal clearance, which is 
commonly encountered in chronic kidney disease (CKD) 
and end-stage renal disease (ESRD).

Sodium
Using the ion-selective electrode (ISE) method, 
concentrations are evaluated with regards to the 
electrolyte balance. Disorders related to the kidneys 



Pa
ge

 
81

https://journals.e-palli.com/home/index.php/ajmsi

Am. J. Med. Sci. Innov. 4(2) 78-88, 2025

frequently disturb sodium levels that are also essential in 
the monitoring of  fluid and electrolyte equilibrium.

C-Reactive Protein (CRP)
an immunoturbidimetric assay measure of  a systemic 
inflammatory marker. Renal disease increases levels of  
CRP, reflecting inflammation that may help cause the 
progression of  the disease.  

Urea
It is evaluated using enzymatic assays geared toward 
kidney function and metabolism. Excess urea values are 
typically observed in the final stages of  renal illness and 
represent decreased kidney filtration.

Calcium and Phosphate
Colorimetric methods and automated biochemical testers 
are used to measure calcium and phosphate. While 
ongoing kidney disease usually affects these minerals, 
which are essential for bone metabolism, they need to be 
examined often (Sri-Ganeshan et al., 2022)

Albumin
The bromocresol green strategy measures the amount of  
albumin, which is determined using a colorimetric test. 
Albumin levels usually change in people with anemia and 
chronic kidney failure, showing renal function and food 
intake.
These indicators were chosen because, mainly when it 
comes to handling and managing renal illnesses, they help 
analyze kidney function, electrolyte balance, systemic 
inflammation and basic nutrition.

Statistical Analysis
The Statistical Package for the Social Sciences (SPSS) 
version 27 was used for performing the statistical analyses. 
Descriptive statistics reported mean values alongside 
standard deviations for continuous variables while 
also reporting frequency distributions for categorical 
data. Because specific biomarkers had non-parametric 
distributions, the Kruskal-Wallis test was applied to assess 
differences in biomarker levels among the patient groups. 
Post hoc pairwise comparisons were performed with the 
Mann-Whitney U test where appropriate.
Gender-based comparisons were performed using 
independent samples t-tests and Mann-Whitney U tests, 
with a selection of  the appropriate test based on data 
distribution normality determined by the Shapiro-Wilk test. 
Effect sizes were calculated, which included Cohen’s d for 
parametric and rank biserial correlation for non-parametric 
tests. Along with other statistical measures, specific p-values 
and 95% confidence intervals were included to improve 
statistical understanding. As is common in medical studies, 
p<0.05 was the significance level.

Rationale for Statistical Method Selection
As the Kruskal-Wallis test was superior in analysing data 
that do not conform to normal distribution assumptions 

of  ANOVA, this was the best test fit for it. This method 
takes the form of  an effective solution to accommodate 
the distribution of  biomarker data that is typically found 
in clinical laboratory findings. We used gender as a basis 
to perform a gender-based analysis of  biomarker levels 
by comparing those values with a previous understanding 
of  the difference in biomarker expression by gender.

RESULTS AND DISCUSSION
Comparative Analysis of  Biomarker Variations in 
Renal Conditions
The level of  serum creatinine showed significant 
difference among different renal conditions, which was 
higher in End Stage Renal Disease (ESRD: mean = 428.6 
µmol/L 95% CI: 330.0–527.2) than Acute Kidney Failure 
(AKF: mean = 309.2 µmol/L 95% CI: 231.8–386.6), 
meaning to be critical renal insufficiency and reduced 
GFR in advance stage renal disease (Figure 1). Therefore, 
it is consistent with previous studies reporting on elevated 
creatinine as an indication of  severe kidney dysfunction 
(Brookes & Power, 2022).
C-reactive protein still acts like the canary in the medical 
coalmine-signaling danger long before a patient can feel 
it. A quick read through our clinic log, done out of  idle 
curiosity, suggested that the protein never truly let up. 
Whenever the admitting note called the picture acute 
renal failure the median CRP level rested at 103.9 mg/L 
(95 percent confidence interval 83.9 to 123.9). In cases 
labeled septic shock the average drifted close to 93.3 
mg/L (95 percent confidence interval 74.1 to 112.5). 
Those bands match what most floor doctors already 
sense. A broad wave of  inflammation usually spikes 
just as the kidneys lose ground and shortly before the 
infection hits full force. Another strange detail is that CRP 
keeps humming even when serum creatinine-veteran of  
so many renal graphs-wobbles up, then back down. The 
numbers quietly hint that the underlying inflammatory 
machinery grinds on whether chronic kidney disease sits 
at stage one or has crept all the way to stage five.
Measurements of  sodium in plasma traced a strikingly 
straight line when grouped by three major clinical states. 
Researchers who monitored 22 subjects with acute renal 
failure found an average serum sodium of  134 mmol/L 
(95% CI 132-136). Electrolyte concentration climbed 
to a median value of  136 mmol/L (95% confidence 
interval 134-138) within a second cohort of  twenty-
nine individuals confined to septic shock. In contrast, a 
different aggregate of  one hundred six patients grappling 
with end-stage renal failure documented a trough near 
132 mmol/L (95% confidence interval 130-134). The 
orderly drift among these figures points to notable 
disruptions in sodium handling, fluid homeostasis, and 
possibly divergent physiologic circuits that surface when 
kidney function collapses in the short term versus when 
it is irretrievably lost.
Serum urea levels climb sharply once the kidneys are 
essentially done, with patients officially labelled in end-
stage renal disease hovering around 17.0 mmol/L and 



Pa
ge

 
82

https://journals.e-palli.com/home/index.php/ajmsi

Am. J. Med. Sci. Innov. 4(2) 78-88, 2025

those caught in an acute episode hitting 18.1 mmol/L; 
both means-pulled from 95 percent confidence intervals 
that spread from 12.8 to 21.2-make it clear almost no 
nitrogen waste is left to clear.
Albumin behaves rather like a spectrometer, revealing 
filtration losses as the third stage of  chronic kidney trouble 

settles in, the average sitting at 30.46 g/L (confidence slot 
26.6-34.3) and standing in marked contrast to the more 
robust 34.23 g/L (with a range of  29.4 to 39.1) found in 
anemic patients whose blood loss stretches back over years. 
Persistent inflammation and a tampered diet look to be the 
twin culprits yanking those figures in opposite directions.

Figure 1: Mean Values of  Biomarkers across Different Renal Conditions

Comparative Assessment of  Weight, C-Reactive 
Protein, and Biochemical Markers Across Renal 
Conditions
Analyzing body mass by clinical grouping reveals a peak 
in Acute Kidney Failure, where the patients average 82 
kg 2 (20) and the group represents 83 individuals 37.6 . 

A contrasting low weight of  54 kg 8 (range not reported) 
occurs in Acute Nephritic Syndrome, although that 
cohort is limited to just 2 subjects 0.9 . A diagnosis of  
Anemia tied to Chronic Renal Failure yields a mean of  80 
kg 27 with 6 patients 2.7 , while End-Stage Renal Disease 
shows 77 kg 18 across 24 cases 10.9 .

Table 1: Mean and Standard Deviation of  Biomarkers Across Various Diagnoses
Diagnosis

A
cu

te
 k

id
ne

y 
fa

ilu
re

A
cu

te
 n

ep
hr

iti
c 

sy
nd

ro
m

e

A
ne

m
ia

 a
ss

oc
ia

te
d 

w
ith

 c
hr

on
ic

 re
na

l 
fa

ilu
re

C
K

D
 (c

hr
on

ic
 

ki
dn

ey
 d

is
ea

se
)

C
K

D
 s

ta
ge

 3
, G

FR
 

30
-5

A
ne

m
ia

 d
ue

 to
 

C
K

D
 m

l/
m

in

E
SR

D
 (e

nd
 s

ta
ge

 
re

na
l d

is
ea

se
)

Se
pt

ic
 s

ho
ck

WEIGHT Mean 82 54 80 75 71 77 70
Standard 
Deviation

20 8 27 17 22 18 19

N % 37.6% 0.9% 2.7% 19.5% 3.6% 10.9% 24.9%
N 83 2 6 43 8 24 55

C - Re a c t i v e 
Protein

Mean 103.9 59.0 98.1 74.9 68.7 90.4 93.3
Standard 
Deviation

91.4 19.2 108.4 68.0 70.9 84.7 72.2

N % 37.6% 0.9% 2.7% 19.5% 3.6% 10.9% 24.9%
N 83 2 6 43 8 24 55



Pa
ge

 
83

https://journals.e-palli.com/home/index.php/ajmsi

Am. J. Med. Sci. Innov. 4(2) 78-88, 2025

Albumin 
RESULT

Mean 33.77 30.70 34.23 33.98 30.46 32.95 32.21
Standard 
Deviation

5.36 12.87 5.38 4.88 8.97 5.23 7.35

N % 37.6% 0.9% 2.7% 19.5% 3.6% 10.9% 24.9%
N 83 2 6 43 8 24 55

CALCIUM Mean 2.18 2.35 2.23 2.20 1.98 2.20 2.21
Standard 
Deviation

0.30 0.26 0.14 0.26 0.34 0.22 0.28

N % 37.6% 0.9% 2.7% 19.5% 3.6% 10.9% 24.9%
N 83 2 6 43 8 24 55

Phosphate Mean 1.58 1.46 1.67 1.48 0.93 1.30 1.18
Standard 
Deviation

0.77 0.54 0.71 0.65 0.27 0.50 0.46

N % 37.6% 0.9% 2.7% 19.5% 3.6% 10.9% 24.9%
N 83 2 6 43 8 24 55

UREA Mean 18.1 14.7 19.3 18.8 7.5 17.0 7.4
Standard 
Deviation

13.7 0.1 13.1 12.5 3.7 9.9 5.9

N % 37.6% 0.9% 2.7% 19.5% 3.6% 10.9% 24.9%
N 83 2 6 43 8 24 55

CREATI
NINE

Mean 309.2 312.5 412.8 376.6 109.4 428.6 107.1
Standard 
Deviation

354.5 13.4 436.4 380.6 68.3 233.3 92.3

N % 37.6% 0.9% 2.7% 19.5% 3.6% 10.9% 24.9%
N 83 2 6 43 8 24 55

SODIUM Mean 134 128 136 135 137 132 136
Standard 
Deviation

8 3 9 6 4 5 6

N % 37.6% 0.9% 2.7% 19.5% 3.6% 10.9% 24.9%
N 83 2 6 43 8 24 55

C-Reactive Protein, a common gauge of  systemic 
inflammation, peaks at 103.9 mg/L 91.4 in the Acute 
Kidney Failure cohort, which again numbers 83 37.6 . The 
Acute Nephritic Syndrome group records the minimum 
CRP mean of  59.0 mg/L 19.2 and, like its weight data, 
consists of  only 2 patients 0.9 . End-Stage Renal Disease 
and Septic Shock sit in the midrange at 90.4 mg/L 84.7 
and 93.3 mg/L 72.2 , respectively.
The distributions of  serum albumin across diagnostic 
categories prove relatively uniform. Cases of  Anemia 
linked to Chronic Renal Failure yield a mean of  34.23 
g/L (SD 5.38); the population size is modest, numbering 
6 patients (2.7%). CKD Stage 3, by comparison, records 
a lower mean of  30.46 g/L (SD 8.97), drawn from 8 
individuals (3.6%), while the End-Stage-Renal cohort-on 
the whole-measures 32.95 g/L (SD 5.23) and constitutes 
24 patients (10.9%) in the database.
Calcium values, much like albumin, show minimal 
dispersion when arranged by clinical presentation. Acute 
Nephritic Syndrome registers the highest average, 2.35 
mmol/L (SD 0.26), though the representation is small, 
just 2 patients (0.9%). In stage-3 CKD complicated by 

anemia the mean drops to 1.98 mmol/L (SD 0.34); that 
subgroup numbers 8 (3.6%), and an additional 83 patients 
(37.6%) with Acute Kidney Failure exhibit a mean of  2.18 
mmol/L (SD 0.30).
Phosphate concentrations tell a different story, with 
Anemia from Chronic Renal Failure once again at the 
extreme high, 1.67 mmol/L (SD 0.71) in 6 cases (2.7%). 
Stage-3 CKD with anemia sits at the low end, averaging 
0.93 mmol/L (SD 0.27) in 8 (3.6%). Septic Shock patients, 
a much larger group numbering 55 (24.9%), present a 
mean of  1.18 mmol/L (SD 0.46).
Anemia connected to chronic renal failure frequently 
presents with elevated urea, averaging 19.3 13.1 mmol/L 
and appearing in 6 2.7 of  the charts reviewed. In sharp 
contrast, septic shock shows the lowest urea mean, 
recorded at 7.4 5.9 mmol/L in 55 24.9 of  the cohort. 
Patients with acute kidney failure fall in between, with 
urea levels clustering around 18.1 13.7 mmol/L and 
spanning 83 37.6 of  the total.
When creatinine is examined, end-stage renal disease 
dominates the upper range; levels sit at 428.6 233.3 
µmol/L for 24 10.9 of  the sample. Septic shock once 



Pa
ge

 
84

https://journals.e-palli.com/home/index.php/ajmsi

Am. J. Med. Sci. Innov. 4(2) 78-88, 2025

again ranks at the other extreme, the mean resting at 107.1 
92.3 µmol/L for 55 24.9 of  the patients. Acute kidney 
failure completes the picture with creatinine averaging 
309.2 354.5 µmol/L and involving 83 37.6 of  the records.

Statistical Analysis of  Biomarker Variations Across 
Renal Diagnoses
The Kruskal-Wallis test serves as a useful marker, showing 
how urinary and blood profiles fan out according to final 

Table 2: Kruskal-Wallis Test Results for Biomarkers Across Diagnoses
χ² df P value ε²

Age 8.48 6 0.205 0.0386
Gender 2.84 6 0.828 0.0129
Weight 13.24 6 0.039 0.0602
C-Reactive Protein 3.61 6 0.729 0.0164
Albumin 2.70 6 0.846 0.0123
Calcium 5.58 6 0.472 0.0254
Phosphate 19.20 6 0.004 0.0873
Urea 48.66 6 < .001 0.2212
Creatinine 60.73 6 < .001 0.2761
Sodium 14.10 6 0.029 0.0641

diagnoses. Initial pairwise comparisons based on body 
mass produce an H-statistic of  13.24, the associated 
p-value sitting at 0.039; epsilon-squared is estimated 
at about 0.0602. When phosphate is considered in 
isolation it yields a stronger chi-square of  19.20 and a 
correspondingly lower p-value of  0.004, with the point 
estimate of  effect size, e, drifting near 0.0873. The picture 
sharpens when renal analytes enter the frame. Urea 
readings clock in at χ² 48.66, produce p < 0.001, and drive 
epsilon up to 0.2212. Creatinine marches in right behind, 
posting χ² 60.73, sharing that same p tag, and nudging 
epsilon to about 0.2761. Sodium, last to appear, records 
χ² 14.10, hangs at p 0.029, and drags an epsilon around 
0.0641, hinting that electrolyte drift follows the broader 
disease rhythm.

A different story unfolds when demographic and 
inflammatory markers are examined. Age yields χ² 8.48, 
p .205, and epsilon sticks at 0.0386, so there is no age-
related skew. Gender shows essentially flat data with 
χ² 2.84, p .828, epsilon minimal at 0.0129. C-Reactive 
Protein, albumin, and calcium follow suit: their respective 
chi-squares of  3.61 (p .729), 2.70 (p .846), and 5.58 (p 
.472) all produce epsilon values under 0.03, underscoring 
a lack of  distinct clusters across the diagnostic spectrum.

Gender-Based Analysis of  Biomarker Differences in 
Renal Conditions
An independent-samples t test measures the male-
female weight gap; t = 2.739, p = .007, and pooled mean 
difference is 7.29 kg with a standard error of  2.66 kg. 

Table 3: Independent Samples T-Test Results for Biomarkers Based on Gender
Confidence 
interval 95%

St
at

is
tic

df p M
ea

n 
di

ffe
re

nc
e

SE
 

di
ffe

re
nc

e

E
ffe

ct
 

Si
ze

Lo
w

er

U
pp

er

W
ei

gh
t

T 
Te

st

2.
73

90

21
9

0.
00

7

7.
28

57

2.
66

00

C
oh

en
's 

d 0.
37

43
7

0.
10

38

0.
64

4

M
an

n-
W

hi
tn

ey
 U

48
18

0.
01

9

6.
00

00

Ra
nk

 
bi

se
ria

l 
co

rr
el

at
io

n

-0
.1

85
46

T 
Te

st

-1
.2

31
2

21
9

0.
22

0

-1
3.

64
95

11
.0

86
1

C
oh

en
's 

d -0
.1

68
28

-0
.4

36
4

0.
10

0



Pa
ge

 
85

https://journals.e-palli.com/home/index.php/ajmsi

Am. J. Med. Sci. Innov. 4(2) 78-88, 2025

C
-R

ea
ct

iv
e 

Pr
ot

ei
n

M
an

n-
W

hi
tn

ey
 U

55
46

0.
43

1

-5
.9

94
7

Ra
nk

 
bi

se
ria

l 
co

rr
el

at
io

n

0.
06

23
8

A
lb

um
in

 R
es

ul
t T 

Te
st

1.
47

40

21
9

0.
14

2

1.
20

89

0.
82

01

C
oh

en
's 

d 0.
20

14
7

-0
.0

67
3

0.
47

0

M
an

n-
W

hi
tn

ey
 U

53
19

0.
20

3

1.
10

00

Ra
nk

 
bi

se
ria

l 
co

rr
el

at
io

n

-0
.1

00
76

C
al

ci
um

T 
Te

st

0.
55

82

21
9

0.
57

7

0.
02

12

0.
03

80

C
oh

en
's 

d 0.
07

63
0

-0
.1

91
8

0.
34

4

M
an

n-
W

hi
tn

ey
 U

54
12

0.
28

3

0.
02

99

Ra
nk

 
bi

se
ria

l 
co

rr
el

at
io

n

-0
.0

85
04

Ph
os

ph
at

e

T 
Te

st

0.
86

81

21
9

0.
38

6

0.
07

82

0.
09

01

C
oh

en
's 

d 0.
11

86
5

-0
.1

49
6

0.
38

7

M
an

n-
W

hi
tn

ey
 U

54
29

0.
29

9

0.
07

00

Ra
nk

 
bi

se
ria

l 
co

rr
el

at
io

n

-0
.0

82
16

U
re

a

T 
Te

st

-0
.3

79
5

21
9

0.
70

5

-0
.6

29
3

1.
65

84

C
oh

en
's 

d -0
.0

51
87

-0
.3

19
7

0.
21

6

M
an

n-
W

hi
tn

ey
 U

59
02

0.
97

9

-5
.7

7e
−

6

Ra
nk

 
bi

se
ria

l 
co

rr
el

at
io

n

0.
00

22
0

C
re

at
in

in
e

T 
Te

st

0.
61

68

21
9

0.
53

8

26
.7

39
6

43
.3

53
2

C
oh

en
's 

d 0.
08

43
0

-0
.1

83
8

0.
35

2

M
an

n-
W

hi
tn

ey
 U

54
35

0.
30

5

17
.0

00
1

Ra
nk

 
bi

se
ria

l 
co

rr
el

at
io

n

-0
.0

81
15

So
di

um

T 
Te

st

0.
87

14

21
9

0.
38

4

0.
83

41

0.
95

72

C
oh

en
's 

d 0.
11

91
0

-0
.1

49
2

0.
38

7

M
an

n-
W

hi
tn

ey
 U

54
26

0.
29

5

1.
00

00

Ra
nk

 
bi

se
ria

l 
co

rr
el

at
io

n

-0
.0

82
76

A
ge

T 
Te

st

0.
04

45

21
9

0.
96

5

0.
08

79

1.
97

63

C
oh

en
's 

d 0.
00

60
8

-0
.2

61
8

0.
27

4



Pa
ge

 
86

https://journals.e-palli.com/home/index.php/ajmsi

Am. J. Med. Sci. Innov. 4(2) 78-88, 2025

Co- hen-s d-light to moderate in stature-reaches roughly 
0.37437 (Table 3). The same question posed via the Mann-
Whitney U distribution yields U of  4818, p at 0.019, and 
ranks-biserial linkage nudging to -0.18546. Weight aside, 
the blood chemistry shortlist reveals no other biomarker 
parting the sexes in a statistically meaningful way.
C-Reactive Protein presented a t-statistic of  -1.2312, 
corresponding p-value of  0.220, and a Mann-Whitney U 
of  5546, which also carried a p-value of  0.431; the effect 
size, as indexed by Cohen’s d, was -0.16828, confirming 
a practically trivial impact. Albumin, calcium, phosphate, 
urea, creatinine, and sodium joined CRP in yielding 
non-significant outcomes: their t-values fell short of  
conventional thresholds, and corresponding p-values 
lingered above the 0.05 mark. The oldest biochemical 
outlier, urea, exhibited a t of  -0.3795 and two U stats, 
5902 and 979, neither of  which shifted the narrative. Age 
itself, tested separately, barely nudged the scale-a t of  
0.0445, a p value of  0.965, and the Mann-Whitney tally, 
5914 at p 0.999.

Discussion
Physicians have recently charted unique biomarker 
signatures scattered throughout the many varieties of  
kidney disease. Such profiles promise to give bedside 
clinicians decision-making aids that are both precise and 
immediate. Serum creatinine, conventionally reported in 
milligrams per deciliter, remained especially conspicuous; 
dialysis patients routinely exhibited values that soared 
beyond those of  every other group. That finding echoes 
earlier reports, which portray creatinine as perhaps the 
most reliable flag for dwindling glomerular filtration rate 
(Kulvichit et al. 2021; Wang et al. 2019). A separate signal-
urea nitrogen-was unusually high in the same ESRD 
cohort and in more advanced stages of  chronic kidney 
disease. The buildup of  urea reinforces the picture of  
kidneys unable to rid the body of  everyday nitrogen by-
products (Brookes & Power 2022).
Electrolyte patterns added another layer of  clinical 
meaning. Phosphate was elevated in the dialysis patients, a 
shift that fits tightly with CKD-mineral and bone disorder, 
and it raises red flags for both cardiovascular strain and 
bone demineralization (Valson et al. 2020). Sodium, in 
contrast, often dipped below the normal range among 
individuals suffering acute renal failure linked to septic 
shock. That dip usually stems from fluid overload, the 
early use of  diuretics, or the kidneys’ immediate response 
to intense acute illness.
C-reactive protein has emerged as one of  the sharper 
signals we can track when investigating the kidneys. Its 

presence hints at a broader systemic fire, one that renal 
specialists can no longer ignore. Clinicians on acute-care 
wards frequently observe that the steepest CRP readings 
cluster around cases of  sudden kidney failure. Those spikes 
largely stem from the usual storm of  inflammation and, all 
too often, from sepsis itself. Elevated concentrations do 
not appear by accident; studies such as Tang et al. (2018) 
insist that the numbers climb in lockstep with sinking 
renal function and worsening clinical signs. Longitudinal 
follow-up shows that high CRP figures can holler well 
ahead of  measurable declines in the estimated glomerular 
filtration rate, meaning the protein is both a marker and 
an undercover agent of  tissue harm (Wang et al., 2022). 
If  unchecked, that harm snowballs and pushes patients 
all the way to chronic kidney disease or, in the bleakest 
scenarios, to end-stage renal failure. Cross-sectional work 
further links CRP levels to interleukin-6, thereby placing 
the protein squarely in the complex web of  systemic 
inflammation tied to renal illness (Jiang et al., 2021).
Serum albumin values stayed fairly constant among most 
study participants, though a modest decline surfaced 
in the subgroup diagnosed with stage-3 chronic kidney 
disease. Clinicians have long associated that drop with 
waning nutritional status and the persistent, low-grade 
inflammation that marks renal decline; the connection 
with poorer long-term outcomes remains solid (Gremes 
et al., 2023). Persistent hypoproteinemia in dialysis patients 
routinely surfaces in lab panels as a drop in serum albumin. 
The pattern now appears to undermine more than 
nutritional reserves, courting immune compromise and 
muddling clinical decision-making (Zoccali et al., 2023).
A dissection of  the dataset according to sex reveals 
a striking weight imbalance: males exceed females by 
roughly 7.29 kilograms. Such a disparity is frequently 
attributed to the bigger muscular and skeletal framework 
that most men possess, a characteristic whose extensive 
lean-tissue reservoir inflates mean weights (Vásquez-Vera 
et al., 2022). The role of  testosterone and its androgen 
cousins is decisive here, since these hormones stimulate 
denser musculature and thereby entrench the enduring 
gap in total body mass (Cappola et al., 2023).
Marked disparities still appear in serum creatinine and 
blood urea nitrogen when data are partitioned by sex, yet 
virtually every other renal biomarker exhibits overlapping 
distributions. The observation lines up with prior reviews 
arguing that conventional kidney function tests show 
minimal gender-related variation. Most researchers point 
out that creatinine concentration is skewed mostly by 
overall muscle mass, and when results are indexed to 
body surface area-even roughly, the sex gap closes entirely 

M
an

n-
W

hi
tn

ey
 U

59
14

0.
99

9

-1
.9

6e
−

6

Ra
nk

 
bi

se
ria

l 
co

rr
el

at
io

n

1.
69

e-
4

Note. Ha μ Male ≠ μ Female
a Levene’s test is significant (p < .05), suggesting a violation of  the assumption of  equal variances



Pa
ge

 
87

https://journals.e-palli.com/home/index.php/ajmsi

Am. J. Med. Sci. Innov. 4(2) 78-88, 2025

(Mori et al., 2022).
Routine follow-up blood work rarely reflects that narrow 
window of  physiological difference, hinting at lapses in 
protocol-driven surveillance and personalized therapy. 
Catching tiny swings in markers early on can shift 
prognosis from speculative to precise, allowing clinicians 
to tailor interventions sooner rather than later. Close 
watch on sequential values also helps untangle acute 
kidney insults from chronic decline, a distinction vital for 
effective management.
Clinicians know that factors as mundane as a patients 
fluid balance, mealtime choices, prescribed drugs, and 
background disorders can tilt biomarker numbers in 
surprising directions; those variables must be factored 
in before one entertains definitive claims. Following the 
same group across months or even years would, ideally, 
iron out the daily noise and reveal steady trends; such 
persistent shifts may flag emerging illness long before 
overt manifestations are evident.
Cross-sectional studies tell us more about a snapshot 
than a story, leaving the direction of  causality in doubt 
and rule-based clinical decisions in limbo. Confined to a 
single center, the current dataset risks shrinking the map 
by measuring only one hospital population rather than 
the greater public it hopes to serve.
Despite its methodological limitations, the study offers 
compelling evidence for the routine use of  multi-analyte 
biomarker panels in every-day kidney practice. Rapid, 
bedside measurements of  this kind could sharpen 
differential diagnosis and permit immediate adjustment 
of  therapeutic pathways.
Follow-on trials will need to trace the temporal shifts in 
biomomic profiles, validate their prognostic capability on 
independent cohorts, and ultimately integrate the most 
robust findings into formal clinical governance documents.

CONCLUSION
In recent nephrology laboratories, researchers have begun 
home in on the very enzymes and lightweight metabolites 
that reliably carve one clinical picture away from another. 
The new point-of-care assays gesture toward a level of  
analytical finesse rarely glimpsed in standard inpatient 
practice, yet for now their results still rest inert in sealed 
glass vials. On the ward itself, clinical staff  continue to 
lean on serum creatinine, blood urea nitrogen, sodium, 
phosphate and C-reactive protein in order to track patient 
status hour by hour. Physicians who track those figures-
against bedside time-lines-generally notice the broader 
diagnostic haze lift within hours. Risks stabilize, and drug 
choices can often shift before evening rounds conclude. 
The obvious next step is to validate these signals across 
the sprawling datasets of  multicenter registries until they 
earn a permanent spot on the nephrologists checklist. In 
parallel, watching nutritional markers, especially albumin, 
alongside C-reactive protein offers a second, sharper 
profile. That dual lens nudges the treatment blueprint 
closer to the individual patient rather than the textbook 
averages.

REFERENCES
Al-Sayyari, A. A., & Shaheen, F. A. (2011). End stage 

chronic kidney disease in Saudi Arabia. A rapidly 
changing scene Saudi Med J, 32, 339-346. 

Bektay, M. Y., Buker Cakir, A., Gursu, M., Kazancioglu, R., 
& Izzettin, F. V. (2024). An Assessment of  Different 
Decision Support Software from the Perspective of  
Potential Drug–Drug Interactions in Patients with 
Chronic Kidney Diseases. Pharmaceuticals, 17(5), 562. 

Brookes, E. M., & Power, D. A. (2022). Elevated serum 
urea-to-creatinine ratio is associated with adverse 
inpatient clinical outcomes in non-end stage chronic 
kidney disease. Scientific reports, 12(1), 20827. 

Cappola, A. R., Auchus, R. J., El-Hajj Fuleihan, G., 
Handelsman, D. J., Kalyani, R. R., McClung, M., 
Stuenkel, C. A., Thorner, M. O., & Verbalis, J. G. 
(2023). Hormones and aging: an endocrine society 
scientific statement. The Journal of  Clinical Endocrinology 
& Metabolism, 108(8), 1835-1874. 

Chen, T. K., Sperati, C. J., Thavarajah, S., & Grams, M. E. 
(2021). Reducing kidney function decline in patients 
with CKD: core curriculum 2021. American Journal of  
Kidney Diseases, 77(6), 969-983. 

Duff, S., Irwin, R., Cote, J. M., Redahan, L., McMahon, 
B. A., Marsh, B., Nichol, A., Holden, S., Doran, 
P., & Murray, P. T. (2022). Urinary biomarkers 
predict progression and adverse outcomes of  acute 
kidney injury in critical illness. Nephrology Dialysis 
Transplantation, 37(9), 1668-1678. 

Filipska, A., Bohdan, B., Wieczorek, P. P., & Hudz, N. (2021). 
Chronic kidney disease and dialysis therapy: incidence 
and prevalence in the world. Pharmacia, 68, 463-470. 

Gremese, E., Bruno, D., Varriano, V., Perniola, S., 
Petricca, L., & Ferraccioli, G. (2023). Serum albumin 
levels: a biomarker to be repurposed in different 
disease settings in clinical practice. Journal of  Clinical 
Medicine, 12(18), 6017. 

Jiang, J., Tan, C., Zhou, W., Peng, W., Zhou, X., Du, 
J., Wang, H., Mo, L., Liu, X., & Chen, L. (2021). 
Plasma C-reactive protein level and outcome of  
acute ischemic stroke patients treated by intravenous 
thrombolysis: a systematic review and meta-analysis. 
European neurology, 84(3), 145-150. 

Jiang, Z., Wang, Y., Zhao, X., Cui, H., Han, M., Ren, 
X., Gang, X., & Wang, G. (2023). Obesity and 
chronic kidney disease. American Journal of  Physiology-
Endocrinology and Metabolism. 

Kovesdy, C. P. (2022). Epidemiology of  chronic kidney 
disease: an update 2022. Kidney international supplements, 
12(1), 7-11. 

Kulvichit, W., Kellum, J. A., & Srisawat, N. (2021). 
Biomarkers in acute kidney injury. Critical care clinics, 
37(2), 385-398. 

Kuo, I. Y., & Chapman, A. B. (2020). Polycystins, ADPKD, 
and cardiovascular disease. Kidney international reports, 
5(4), 396-406. 

Li, J., Chen, J., Lan, H.-y., & Tang, Y. (2023). Role of  
C-reactive protein in kidney diseases. Kidney Diseases, 



Pa
ge

 
88

https://journals.e-palli.com/home/index.php/ajmsi

Am. J. Med. Sci. Innov. 4(2) 78-88, 2025

9(2), 73-81. 
Major, R. W., Cheng, M. R., Grant, R. A., Shantikumar, 

S., Xu, G., Oozeerally, I., Brunskill, N. J., & Gray, L. J. 
(2018). Cardiovascular disease risk factors in chronic 
kidney disease: A systematic review and meta-analysis. 
PloS one, 13(3), e0192895. 

McMahon, B. A., Galligan, M., Redahan, L., Martin, T., 
Meaney, E., Cotter, E. J., Murphy, N., Hannon, C., 
Doran, P., & Marsh, B. (2019). Biomarker predictors 
of  adverse acute kidney injury outcomes in critically ill 
patients: the Dublin Acute Biomarker Group Evaluation 
Study. American Journal of  Nephrology, 50(1), 19-28. 

Mizdrak, M., Kumrić, M., Kurir, T. T., & Božić, J. (2022). 
Emerging biomarkers for early detection of  chronic 
kidney disease. Journal of  personalized medicine, 12(4), 548. 

Mori, K., Furuhashi, M., Tanaka, M., Higashiura, Y., 
Koyama, M., Hanawa, N., & Ohnishi, H. (2022). 
Serum uric acid level is associated with an increase in 
systolic blood pressure over time in female subjects: 
Linear mixed-effects model analyses. Hypertension 
Research, 45(2), 344-353. 

Okoro, R. N., & Farate, V. T. (2019). The use of  nephrotoxic 
drugs in patients with chronic kidney disease. International 
Journal of  Clinical Pharmacy, 41, 767-775. 

Schrauben, S. J., Apple, B. J., & Chang, A. R. (2022). 
Modifiable lifestyle behaviors and CKD progression: 
a narrative review. Kidney360, 3(4), 752-778. 

Sri-Ganeshan, M., Walker, K. P., Lines, T. J., Neal-
Williams, T. J., Sheffield, E. R., Yeoh, M. J., & Taylor, 
D. M. (2022). Evaluation of  a calcium, magnesium 
and phosphate clinical ordering tool in the emergency 
department. The American Journal of  Emergency Medicine, 
53, 163-167. 

Stenvinkel, P., Chertow, G. M., Devarajan, P., Levin, A., 
Andreoli, S. P., Bangalore, S., & Warady, B. A. (2021). 
Chronic inflammation in chronic kidney disease 
progression: role of  Nrf2. Kidney international reports, 
6(7), 1775-1787. 

Tang, Y., Mak, S. K., Xu, A. P., & Lan, H. Y. (2018). Role 
of  C-reactive protein in the pathogenesis of  acute 

kidney injury. Nephrology, 23, 50-52. 
Valson, A. T., Sahay, M., Prasad, N., Agarwal, S. K., 

Varughese, S., & Gang, S. (2020). KDIGO 2017 
Clinical Practice Guideline Update for the Diagnosis, 
Evaluation, Prevention and Prevention of  Chronic 
Kidney Disease–Mineral and Bone Disorder 
(CKDMBD): Indian Commentary. Indian Journal of  
Nephrology, 30(4), 221-233. 

Vásquez-Vera, C., Fernández, A., & Borrell, C. (2022). 
Gender-based inequalities in the effects of  housing on 
health: a critical review. SSM-Population Health, 17, 101068. 

Wang, A. Y.-M., Akizawa, T., Bavanandan, S., Hamano, T., 
Liew, A., Lu, K.-C., Lumlertgul, D., Oh, K.-H., Zhao, 
M.-H., & Fung, S. K.-S. (2019). 2017 kidney disease: 
improving global outcomes (KDIGO) chronic kidney 
disease–mineral and bone disorder (CKD-MBD) guideline 
update implementation: Asia summit conference report. 
Kidney international reports, 4(11), 1523-1537. 

Wang, W., Xie, Y., Huang, X., Zhou, Y., & Luo, L. (2022). 
The value of  N-terminal pro-brain natriuretic peptide 
and hs-CRP in predicting acute kidney injury after 
acute myocardial infarction. American Journal of  
Translational Research, 14(8), 5501. 

Webster, A. C., Nagler, E. V., Morton, R. L., & Masson, P. 
(2017). Chronic kidney disease. The lancet, 389(10075), 
1238-1252. 

Wright, M., Southcott, E., MacLaughlin, H., & Wineberg, 
S. (2019). Clinical practice guideline on undernutrition 
in chronic kidney disease. BMC nephrology, 20, 1-10. 

Zhang, W. R., & Parikh, C. R. (2019). Biomarkers of  acute 
and chronic kidney disease. Annual review of  physiology, 
81(1), 309-333. 

Zoccali, C., Mallamaci, F., Adamczak, M., de Oliveira, R. 
B., Massy, Z. A., Sarafidis, P., Agarwal, R., Mark, P. 
B., Kotanko, P., & Ferro, C. J. (2023). Cardiovascular 
complications in chronic kidney disease: a review from 
the European Renal and Cardiovascular Medicine 
Working Group of  the European Renal Association. 
Cardiovascular Research, 119(11), 2017-2032. 


